IPN.PA - Ipsen S.A.

Paris - Paris Verzögerter Preis. Währung in EUR

Ipsen S.A.

65, quai Georges Gorse
Cedex
Boulogne-Billancourt 92650
France
33 1 58 33 50 00
http://www.ipsen.com

SektorHealthcare
BrancheDrug Manufacturers—Specialty & Generic
Vollzeitmitarbeiter5.807

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. David LoewCEO & DirectorN/AN/A1967
Mr. Aymeric Le ChatelierExec. VP & CFON/AN/A1969
Dr. Aidan MurphyExec. VP of Technical OperationsN/AN/A1966
Ms. Eugenia LitzVP of Investor RelationsN/AN/AN/A
Mr. François GarnierExec. VP & Gen. CounselN/AN/A1962
Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis and Roche. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Corporate Governance

Ipsen S.A.s ISS Governance QualityScore, Stand 7. Dezember 2019, lautet 8. Die grundlegenden Scores sind Audit: 1, Vorstand: 7, Shareholderrechte: 7, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.
Mit Yahoo Nutzung stimmen Sie zu, dass Yahoo und Partner Cookies für Personalisierungs- und andere Zwecke nutzen